Vectorite Biomedical Inc. (4170.TWO) Stock
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally.
Valuation
Financials & Margins
Valuation & Return Ratios
About Vectorite Biomedical Inc.
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. The company is involved in cell preparation product manufacturing; and collection and storage of immune cells. Its products are used in the field of infectious diseases and inflammation, cancer, and oncology. The company was incorporated in 2004 and is based in New Taipei City, Taiwan.
Vectorite Biomedical Inc. is led by CEO Kechang Ou, employs 43 people, headquartered in New Taipei City, TW, publicly traded since 2013.
Vectorite Biomedical Inc. (4170.TWO) stock trades at $12.00 with a market capitalization of $525.26M. The stock is valued at a price-to-earnings (P/E) ratio of 4.46, price-to-book of 1.03, price-to-sales of 9.58. Over the past 52 weeks the stock has ranged between $11.50 and $18.15, and currently trades 33.9% below its 52-week high.
On profitability, Vectorite Biomedical Inc. generates a return on equity (ROE) of 26.13%, above the typical market range of roughly 12-15%, an operating margin of -31.82%, a net profit margin of 215.70%.
Official website: www.vectorite.com.tw
Vectorite Biomedical Inc. (4170.TWO) — frequently asked questions
What is Vectorite Biomedical Inc. (4170.TWO) stock price today?
Vectorite Biomedical Inc. (4170.TWO) is currently trading at $12.00, down 1.64% today.
What is 4170.TWO P/E ratio?
Vectorite Biomedical Inc.'s P/E ratio is 4.46. This is below the typical market average of roughly 18-22x. A low P/E can reflect a lower valuation, slower expected growth, or both.
What is 4170.TWO return on equity (ROE)?
Vectorite Biomedical Inc.'s return on equity (ROE) is 26.13%. ROE measures net income relative to shareholders' equity. This is above the typical market range of roughly 12-15%.
What is Vectorite Biomedical Inc.'s market cap?
Vectorite Biomedical Inc. has a market capitalization of $525.26M.
Does 4170.TWO pay a dividend?
Vectorite Biomedical Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does 4170.TWO carry?
Vectorite Biomedical Inc. has a debt-to-equity ratio of 0.00. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is 4170.TWO's profit margin?
Vectorite Biomedical Inc. reports a net profit margin of 215.70% — the share of revenue left after every cost, including tax and interest.
What sector is 4170.TWO in?
Vectorite Biomedical Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is 4170.TWO listed on?
Vectorite Biomedical Inc. trades on TWO under the ticker 4170.TWO.
What is 4170.TWO's 52-week range?
Over the last year Vectorite Biomedical Inc. has traded between $11.50 and $18.15.
Related Healthcare Stocks
Popular Stocks
Screens 4170.TWO currently matches
On the figures above, Vectorite Biomedical Inc. passes the filters for 21 of our ready-made screens, among them Low PE Stocks, Small Cap Stocks, Stocks With PE Under 20. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.